MXCT

1.3807.81%
MM

Maher Masoud

President, CEO & Executive Director

Mr. Maher Masoud is President, CEO & Executive Director of MaxCyte, Inc. since January 1, 2024 and served as its Head of Global Business Development and Legal Officer since November 2023 and had been its Secretary since July 2021 until December 2023 and had been its Executive Vice President from January 2020 to January 1, 2024. Mr. Masoud served as General Counsel of MaxCyte, Inc. since January 2020 until November 2023 and as its Vice President of Legal since May 2017 until January 2020. Mr. Masoud started his biopharmaceutical career as a research associate with Glen Research before joining Human Genome Sciences as Director and Corporate Counsel, overseeing legal activities for the company?s global clinical trials, until its acquisition by GlaxoSmithKline. Mr. Masoud has experience as an attorney and general counsel in the biotech industry. He has served as Assistant General Counsel and Corporate Secretary for Wellstat Management Company from July 2015 to May 2017. Mr. Masoud managed the legal team on the launch of two FDA-approved drugs while at Wellstat. He was a co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors and Corporate Attorney at Human Genome Sciences, Inc. from 2006 to 2012. At Human Genome Sciences, he assisted with FDA compliance for the product launch of Benlysta, negotiated and executed more than 1,000 clinical trial agreements, negotiated licensing deals and assisted it with raising financing through bond and secondary stock offerings. A member of the Maryland State Bar, Mr. Masoud received his J.D. from Michigan State University College of Law and a B.S. in cell and molecular biology genetics from the University of Maryland.

Positions